GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — are ... adults who have obesity are good candidates for these medications ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...